Author: "Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )" / Publisher: wiley - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )"' showing total 26 results

Start Over Author "Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )" Publisher wiley

26 results on '"Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )"'

1. Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome‐enriched vesicles

Author: Michel Record, Mehdi Attia, Kevin Carayon, Laly Pucheu, Julio Bunay, Régis Soulès, Silia Ayadi, Bruno Payré, Laure Perrin‐Cocon, Florence Bourgailh, Antonin Lamazière, Vincent Lotteau, Marc Poirot, Sandrine Silvente‐Poirot, Philippe de Medina, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Microscopie Électronique Appliquée à la Biologie (CMEAB), Toulouse Réseau Imagerie-Genotoul ( TRI-Genotoul), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Poirot, Marc
Subjects: bis(monoacylglycero)phosphate, Histology, viruses, [SDV]Life Sciences [q-bio], Imidazoles, virus diseases, differentiation, Cell Biology, respiratory system, Exosomes, Lysobisphosphatidic acid, [SDV] Life Sciences [q-bio], Mice, Cholesterol, Neoplasms, dendrogenin A, cancer, Animals, nuclear receptor, Cholestanols, Liver X Receptors
Abstract: International audience; Tumour cells are characterized by having lost their differentiation state. They constitutively secrete small extracellular vesicles (sEV) called exosomes when they come from late endosomes. Dendrogenin A (DDA) is an endogenous tumour suppressor cholesterol-derived metabolite. It is a new class of ligand of the nuclear Liver X receptors (LXR) which regulate cholesterol homeostasis and immunity. We hypothesized that DDA, which induces tumour cell differentiation, inhibition of tumour growth and immune cell infiltration into tumours, could functionally modify sEV secreted by tumour cells. Here, we have shown that DDA differentiates tumour cells by acting on the LXRβ. This results in an increased production of sEV (DDA-sEV) which includes exosomes. The DDA-sEV secreted from DDA-treated cells were characterized for their content and activity in comparison to sEV secreted from control cells (C-sEV). DDA-sEV were enriched, relatively to C-sEV, in several proteins and lipids such as differentiation antigens, "eat-me" signals, lipidated LC3 and the endosomal phospholipid bis(monoacylglycero)phosphate, which stimulates dendritic cell maturation and a Th1 T lymphocyte polarization. Moreover, DDA-sEV inhibited the growth of tumours implanted into immunocompetent mice compared to control conditions. This study reveals a pharmacological control through a nuclear receptor of exosome-enriched tumour sEV secretion, composition and immune function. Targeting the LXR may be a novel way to reprogram tumour cells and sEV to stimulate immunity against cancer.
Published: 2022

2. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer

Author: Janick Selves, Valérie Jooste, Laurent Martin, Dominique Guenot, Alex Duval, Côme Lepage, Sylviane Olschwang, Michè le Legrain, Laetitia Marisa, Anne-Marie Bouvier, Delphine Lecorre, Sylvain Kirzin, Marie-Christine Etienne-Grimaldi, Gérard Milano, Gilles Manceau, Marie-Pierre Gaub, Valérie Boige, Pierre Laurent-Puig, Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Universitaire de Cancérologie [Paris] (IUC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer (LNCC), Institut Gustave Roussy (IGR), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biochimie et de Biologie Moléculaire, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Progression tumorale et microenvironnement. Approches translationnelles et épidémiologie, Université de Strasbourg (UNISTRA)-CHU Strasbourg-Les Hôpitaux Universitaires de Strasbourg (HUS)-Institut Régional du Cancer-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC), Laboratoire d'Oncopharmacologie (EA 3836), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génétique Médicale et Génomique Fonctionnelle (GMGF), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de génétique médicale [Hôpital de la Timone - APHM], Institut National de la Santé et de la Recherche Médicale (INSERM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Département d'Oncologie [Hôpital Clairval - Marseille], Hôpital Privé Clairval [Marseille], Hôpital Européen [Fondation Ambroise Paré - Marseille], Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Service d'anatomie et de cytologie pathologiques, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de chirurgie digestive et hépato-bilio-pancréatique [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Institut Universitaire de Cancérologie, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), HAL-UPMC, Gestionnaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Universitaire de Cancérologie [Sorbonne Université] (IUC), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique ( MEPPOT - U1147 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Cartes d'Identité des Tumeurs ( CIT ), Institut Gustave Roussy ( IGR ), Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Strasbourg ( UNISTRA ) -Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC)-Institut Régional du Cancer-Les Hôpitaux Universitaires de Strasbourg (HUS)-CHU Strasbourg, Laboratoire d'Oncopharmacologie ( EA 3836 ), Centre de Recherche en Cancérologie de Toulouse ( CRCT ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Génétique Médicale et Génomique Fonctionnelle ( GMGF ), Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) -Aix Marseille Université ( AMU ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )
Subjects: Male, Cancer Research, Pathology, Colorectal cancer, Kaplan-Meier Estimate, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, Prospective Studies, Stage (cooking), Prospective cohort study, Aged, 80 and over, 0303 health sciences, Univariate analysis, Middle Aged, 3. Good health, mismatch repair, colon cancer, Oncology, 030220 oncology & carcinogenesis, Colonic Neoplasms, Female, DNA mismatch repair, France, Adult, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Young Adult, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, neoplasms, Aged, Neoplasm Staging, 030304 developmental biology, Point mutation, Microsatellite instability, Biomarker, PIK3CA, mutations, medicine.disease, Confidence interval, Mutation, microsatellite instability, prognosis, Neoplasm Recurrence, Local, Microsatellite Repeats
Abstract: International audience; PIK3CA, which encodes the p110α catalytic subunit of PI3Kα, is one of the most frequently altered oncogenes in colon cancer (CC), but its prognostic value is still a matter of debate. Few reports have addressed the association between PIK3CA mutations and survival and their results are controversial. In the present study, we aimed to clarify the prognostic impact of PIK3CA mutations in stage I–III CC according to mismatch repair status. Fresh frozen tissue samples from two independent cohorts with a total of 826 patients who underwent curative surgical resection of CC were analyzed for microsatellite instability and screened for activating point mutations in exon 9 and 20 of PIK3CA by direct sequencing. Overall, 693 tumors (84%) exhibited microsatellite stability (MSS) and 113 samples (14%) harbored PIK3CA mutation. In the retrospective training cohort (n = 433), patients with PIK3CA-mutated MSS tumors (n = 47) experienced a significant increased 5-year relapse-free interval compared with PIK3CA wild-type MSS tumors (n = 319) in univariate analysis (94% vs. 68%, Log-rank P = 0. 0003) and in multivariate analysis (HR = 0.12; 95% confidence interval, 0.029–0.48; P = 0.0027). In the prospective validation cohort (n = 393), the favorable prognostic impact of PIK3CA mutations in MSS tumors (n = 327) was confirmed (83% vs. 67%, Log-rank P = 0.04). Our study showed that PIK3CA mutations are associated with a good prognosis in patients with MSS stage I–III CC.
Published: 2015

3. No survival improvement in patients with high‐risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades

Author: Carole Barin, Lotfi Benboubker, Cyrille Touzeau, Nicolas Vallet, Olivier Theisen, Pascal Godmer, Thomas Chalopin, Hervé Avet-Loiseau, Olivier Herault, Steven Le Gouill, Marlene Ochmann, Philippe Moreau, Mourad Tiab, Emmanuel Gyan, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, Université de Bretagne Sud - Vannes (UBS Vannes), Université de Bretagne Sud (UBS), ERL 7001 LNOx (Leukemic Niche & redOx metabolism / Niche leucémique et métabolisme redOx) (LNOx), Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours-Université de Tours-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service d'Hématologie [Nantes], Site de Recherche Intégrée sur le Cancer [Nantes] (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making [Nantes] (ILIAD), Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Tours (UT)-Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre National de la Recherche Scientifique (CNRS)-Microenvironnement des niches tumorales (CNRS GDR 3697 Micronit ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours (UT)-Université de Tours (UT), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Bernardo, Elizabeth
Subjects: Adult, Male, Oncology, medicine.medical_specialty, MEDLINE, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Text mining, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, In patient, ComputingMilieux_MISCELLANEOUS, Multiple myeloma, Aged, Retrospective Studies, Aged, 80 and over, Chromosome Aberrations, business.industry, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 3. Good health, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, business, 030215 immunology
Abstract: International audience; No abstract available
Published: 2021

4. Understanding human γδ T cell biology toward a better management of cytomegalovirus infection

Author: Vincent Pitard, Florent Guerville, Gabriel Marsères, Jean-Jacques Fournié, Julie Déchanet-Merville, Pierre Merville, Anaïs Cosentino, Hannah Kaminski, Lionel Couzi, Immunology from Concept and Experiments to Translation (ImmunoConcept), Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, T cell, Immunology, Congenital cytomegalovirus infection, Biology, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Immune system, T-Lymphocyte Subsets, Receptors, medicine, Humans, Immunology and Allergy, Receptor, gamma-delta, Endothelial protein C receptor, T-cell receptor, Hematopoietic Stem Cell Transplantation, Receptors, Antigen, T-Cell, gamma-delta, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, T-Cell, medicine.disease, Phenotype, 3. Good health, 030104 developmental biology, medicine.anatomical_structure, Antigen, Cytomegalovirus Infections, Annexin A2, 030215 immunology
Abstract: International audience; Cytomegalovirus (CMV) infection is responsible for significant morbidity and mortality in immunocompromised patients, namely solid organ and hematopoietic cell transplant recipients, and can induce congenital infection in neonates. There is currently an unmet need for new management and treatment strategies. Establishment of an anti-CMV immune response is critical in order to control CMV infection. The two main human T cells involved in HCMV-specific response are αβ and non-Vγ9Vδ2 T cells that belong to γδ T cell compartment. CMV-induced non-Vγ9Vδ2 T cells harbor a specific clonal expansion and a phenotypic signature, and display effector functions against CMV. So far, only two main molecular mechanisms underlying CMV sensing have been identified. Non-Vγ9Vδ2 T cells can be activated either by stress-induced surface expression of the γδT cell receptor (TCR) ligand annexin A2, or by a multimolecular stress signature composed of the γδTCR ligand endothelial protein C receptor and co-stimulatory signals such as the ICAM-1-LFA-1 axis. All this basic knowledge can be harnessed to improve the clinical management of CMV infection in at-risk patients. In particular, non-Vγ9Vδ2 T cell monitoring could help better stratify the risk of infection and move forward a personalized medicine. Moreover, recent advances in cell therapy protocols open the way for a non-Vγ9Vδ2 T cell therapy in immunocompromised patients.
Published: 2020

5. Deciphering human γδ T cell response in cancer: Lessons from tumor‐infiltrating γδ T cells

Author: Elena Lo Presti, Francesco Dieli, Serena Meraviglia, Jean-Jacques Fournié, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Lo Presti E., Dieli F., Fournie J.J., and Meraviglia S.
Subjects: 0301 basic medicine, [SDV]Life Sciences [q-bio], medicine.medical_treatment, T cell, Immunology, Context (language use), Biology, Tumor-infiltrating lymphocytes, clinical correlation,colon cancer, tumor microenvironment, tumor-infiltrating lymphocytes, γδ T lymphocytes, Clinical correlazion, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, 0302 clinical medicine, T-Lymphocyte Subsets, Neoplasms, medicine, Humans, Immunology and Allergy, ComputingMilieux_MISCELLANEOUS, Tumor microenvironment, Effector, Cancer, Receptors, Antigen, T-Cell, gamma-delta, Immunotherapy, Gamma-delta T lymphocytes, medicine.disease, Colon cancer, 3. Good health, 030104 developmental biology, medicine.anatomical_structure, Cancer research, Ex vivo, 030215 immunology
Abstract: The finding that γδ T cells are present among tumor-infiltrating lymphocytes in humans suggests they participate in tumor immune surveillance, but their relevance is unclear because the relative abundance of tumor-infiltrating γδ T cells correlates with positive or negative, or even do not correlate with prognosis. This likely depends on the fact that tumor-infiltrating γδ T cells may play substantially different effector or regulatory functions, and correlation with patient's prognosis relies on distinct γδ T cell subsets in the context of the tumor. There is interest to exploit γδ T cells in tumor immunotherapy, but to make this approach successful there is urgent need to fully understand the biological functions of γδ T cells and of how they can be manipulated in vivo and ex vivo to safely provide benefit to the host. This review focuses on our previous and ongoing studies of tumor-infiltrating γδ T lymphocytes in different types of human cancer. Moreover, we discuss the interaction of tumor-infiltrating γδ T cells with other cells and molecules present in the tumor microenvironment, and their clinical relevance on the ground, that deep knowledge in this field can be used further for better immunotherapeutic intervention in cancer.
Published: 2020

6. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort

Author: Laurent Guilleminault, Lise Rosencher, A. Proust, Arnaud Bourdin, Clairelyne Dupin, S. Fry, Drifa Belhadi, Cécile Chenivesse, Patrick Berger, Frédéric de Blay, Alain Didier, Anne‐Sophie Gamez, Camille Couffignal, Philippe Bonniaud, Gilles Garcia, Camille Taillé, Pierre-Olivier Girodet, Chantal Raherison, Christophe Leroyer, Geneviève Le Bourdellès, Guillaume Mahay, MORNET, Dominique, Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université européenne de Bretagne - European University of Brittany (UEB), CHU Rouen, Normandie Université (NU), Université de Bordeaux (UB), Centre d'Investigation Clinique - Epidemiologie Clinique / Essais Cliniques Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de pneumologie [Hôpital Foch], Hôpital Foch [Suresnes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris-Sud - Paris 11 (UP11), Université Paris-Saclay, Hôpital Bicêtre, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service Pneumologie et allergologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre d'Investigation Clinique – Épidémiologie Clinique [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Service de pneumologie et allergologie pédiatrique [CHU Toulouse]
Subjects: Male, 0301 basic medicine, Hypereosinophilia, Severity of Illness Index, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 0302 clinical medicine, Prednisone, Interquartile range, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, oral steroid, MESH: Antibodies, Monoclonal, Humanized / adverse effects, MESH: Middle Aged, EPICENE, MESH: Follow-Up Studies, Middle Aged, Dupilumab, 3. Good health, Cohort, Female, France, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.symptom, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, Cohort study, medicine.drug, Adult, medicine.medical_specialty, Immunology, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, T2 inflammation, MESH: Severity of Illness Index, Internal medicine, side‐effect, medicine, Humans, MESH: Asthma / physiopathology, hypereosinophilia, MESH: Antibodies, Monoclonal, Humanized / administration & dosage, Retrospective Studies, Asthma, MESH: Humans, business.industry, MESH: Adult, MESH: Retrospective Studies, Retrospective cohort study, MESH: Asthma / drug therapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, asthma, medicine.disease, MESH: Male, MESH: France, 030104 developmental biology, 030228 respiratory system, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH: Asthma / blood, business, MESH: Female, Follow-Up Studies
Abstract: International audience; Background: Dupilumab is a monoclonal anti‐IL‐4Rα antibody developed for the treatment of severe asthma (SA). An early access programme for dupilumab was opened in France in SA patients experiencing unacceptable steroids side‐effects and/or life‐threatening exacerbations.Objective: To assess changes in asthma control between baseline and 12 months of treatment.Methods: Multi‐centre (n = 13) retrospective real‐life cohort study. This study is registered on ClinicalTrials.gov (NCT04022447).Results: Overall, 64 patients with SA (median age 51, interquartile range [44‐61]; 53% females) received dupilumab as add‐on therapy to maximal standard of care; and 76% were on oral daily steroids at baseline. After 12 months, median asthma control test score improved from 14 [7‐16] to 22 [17‐24] (P < .001); median forced expiratory volume in 1 seconds increased from 58% [47‐75] to 68% [58‐88] (P = .001); and daily prednisone dose was reduced from 20 [10‐30] to 5 [0‐7] mg/d (P < .001). Annual exacerbations decreased from 4 [2‐7] to 1 [0‐2] (P < .001). Hypereosinophilia ≥1500/mm3 was observed at least once during follow‐up in 16 patients (25%), persisting after 6 months in 8 (14%) of them. Increase in blood eosinophil count did not modify the clinical response during the study period. Injection‐site reaction was the most common side effect (14%). Three deaths were observed, none related to treatment by investigators.Conclusion & clinical relevance: In this first real‐life cohort study of predominantly steroid‐dependent SA, dupilumab significantly improved asthma control and lung function and reduced oral steroids use and exacerbations rate. Despite limitations due to the retrospective study, these results are consistent with controlled trials efficacy data. Further studies are required to assess the clinical significance and long‐term prognosis of sustained dupilumab‐induced hypereosinophilia.
Published: 2020

7. Curing inflammatory diseases using phosphorous dendrimers

Author: Anne‐Marie Caminade, Cédric‐Olivier Turrin, Rémy Poupot, Laboratoire de chimie de coordination (LCC), Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Toulouse, Inserm, Centre National de la Recherche Scientifique (CNRS), Gulli, Marie-Hélène, Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Inflammation, Dendrimers, Dendrimer, Anti-Inflammatory Agents, Biomedical Engineering, Medicine (miscellaneous), Phosphorus, Bioengineering, [CHIM.COOR] Chemical Sciences/Coordination chemistry, Monocytes, Mice, Leukocytes, Mononuclear, Animals, [CHIM.COOR]Chemical Sciences/Coordination chemistry
Abstract: International audience; Different types of water-soluble phosphorous dendrimers have been synthesized and display many different biological properties. It has been shown in particular that phosphorous dendrimers of first generation functionalized with azabisphosphonate terminal functions are able to stimulate the human immune system ex vivo. These dendrimers are internalized by monocytes within a few seconds, and induce their anti-inflammatory activation. The presence of the dendrimers induces also the inhibition of the differentiation of monocytes into osteoclasts, the maturation of dendritic cells, and inhibits the proliferation of the proinflammatory CD4+ T lymphocytes. Finally, after 2–3 weeks of culture of peripheral blood mononuclear cells, amplifications by several tens of natural killer cells is observed. In view of all these properties, the influence of these azabisphosphonate-dendrimers has been tested in vivo with several animal models, against different chronic or acute inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, uveitis, and psoriasis, but also against myeloid leukemia, a hematological cancer. The hematological safety has been demonstrated in mice, as there is no platelet aggregation, no hemolysis, and no disturbance in the hematological formula. The safety of the azabisphosphonate-dendrimer has been assessed also with non-human primates (cynomolgus monkeys) which received repeated injections, as a de-risking pre-clinical test. Biochemical, hematological, and all immunological parameters in peripheral blood remained within a normal physiological range throughout the study, and all survived well. Other phosphorous dendrimers also display anti-inflammatory properties in vivo, in particular dendrimers functionalized with mannose derivatives, which prevent acute lung diseases when given orally (per os) to mice.
Published: 2022

8. Does HEV‐3 subtype play a role in the severity of acute hepatitis E?

Author: Jacques Izopet, Jean-Marie Péron, Mathilde Castanier, Florence Abravanel, Sébastien Lhomme, Nassim Kamar, Chloé Dimeglio, PINIER, CHRISTINE, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: Multivariate analysis, Genotype, viruses, Stepwise regression analysis, hepatitis E virus, medicine.disease_cause, subtype, MESH: Genotype, 03 medical and health sciences, 0302 clinical medicine, Hepatitis E virus, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, pathogenicity, Medicine, Prospective Studies, MESH: Hepatitis E* / diagnosis, MESH: Phylogeny, Virus load, Phylogeny, MESH: Hepatitis E virus* / genetics, MESH: Humans, MESH: Hepatitis E* / epidemiology, Hepatology, business.industry, Acute hepatitis E, Hepatitis E virus genotype, Pathogenicity, Virology, MESH: Prospective Studies, Hepatitis E, Europe, MESH: RNA, Viral, 030220 oncology & carcinogenesis, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, RNA, Viral, 030211 gastroenterology & hepatology, MESH: Europe, business, hospitalization, Acute hepatitis
Abstract: International audience; Hepatitis E virus genotype 3 (HEV-3) is a major aetiologic agent of acute hepatitis in industrialized countries. Two main HEV-3 subtypes are found in Europe: subtypes 3c and 3f. We have analysed the clinical and biological parameters from 100 French immunocompetent patients with an HEV subtype 3f or subtype 3c infection, included in a prospective multicentre study. Stepwise regression analysis found that infections with HEV subtype 3f were associated with fever (OR: 6.1 95%CI: 1.4-26.1), have a greater virus load (OR: 7.4; 95%CI: 1.3-42.2) and require more frequent hospitalization (OR: 7.6; 95%CI: 1.1-51.4) than those infected with subtype 3c. The directed acyclic graph strengthens the multivariate analyses indicating a direct link between the HEV subtype, HEV RNA concentration, fever and hospitalization. Further studies on patients in other European countries are needed to confirm this relationship and determine the underlying mechanism
Published: 2019

9. Histamine in murine narcolepsy: What do genetic and immune models tell us?

Author: Anne-Laure Morel, Silvia Melzi, Roland S. Liblau, Céline Scoté-Blachon, Yves Dauvilliers, Christelle Peyron, Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Peyron, Christelle, APPEL À PROJETS GÉNÉRIQUE 2018 - Physiopathologie de la narcolepsie de type 1 - - NARCO-T12018 - ANR-18-CE17-0014 - AAPG2018 - VALID, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Montpellier (INM), and ANR-18-CE17-0014,NARCO-T1,Physiopathologie de la narcolepsie de type 1(2018)
Subjects: MESH: Histamine* / metabolism, [SDV]Life Sciences [q-bio], MESH: Histidine Decarboxylase / genetics, Histidine Decarboxylase, Mixed Function Oxygenases, Mice, chemistry.chemical_compound, MESH: Narcolepsy* / genetics, 0302 clinical medicine, MESH: Orexins / metabolism, MESH: Animals, hypothalamus, 0303 health sciences, Microglia, General Neuroscience, MESH: Mixed Function Oxygenases, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, Hypothalamus, [SDV.IMM]Life Sciences [q-bio]/Immunology, Histamine, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Biology, Pathology and Forensic Medicine, 03 medical and health sciences, Internal medicine, medicine, Animals, Humans, RNA, Messenger, sleep, MESH: Mice, Neuroinflammation, MESH: RNA, Messenger, Narcolepsy, 030304 developmental biology, MESH: Narcolepsy* / metabolism, Orexins, MESH: Humans, Histaminergic, medicine.disease, Pons, Orexin, Endocrinology, orexin, nervous system, chemistry, Neurology (clinical), hypocretin, 030217 neurology & neurosurgery
Abstract: International audience; An increased number of histaminergic neurons, identified by labeling histidine-decarboxylase (HDC) its synthesis enzyme, was unexpectedly found in patients with narcolepsy type 1 (NT1). In quest for enlightenment, we evaluate whether an increase in HDC cell number and expression level would be detected in mouse models of the disease, in order to provide proof of concepts reveling possible mechanisms of compensation for the loss of orexin neurons, and/or of induced expression as a consequence of local neuroinflammation, a state that likely accompanies NT1. To further explore the compensatory hypothesis, we also study the noradrenergic wake-promoting system. Immunohistochemistry for HDC, orexin, and melanin-concentrating hormone (MCH) was used to count neurons. Quantitative-PCR of HDC, orexin, MCH, and tyrosine-hydroxylase was performed to evaluate levels of mRNA expression in the hypothalamus or the dorsal pons. Both quantifications were achieved in genetic and neuroinflammatory models of narcolepsy with major orexin impairment, namely the orexin-deficient (Orex-KO) and orexin-hemagglutinin (Orex-HA) mice respectively. The number of HDC neurons and mRNA expression level were unchanged in Orex-KO mice compared to controls. Similarly, we found no change in tyrosine-hydroxylase mRNA expression in the dorsal pons between groups. Further, despite the presence of protracted local neuroinflammation as witnessed by the presence of reactive microglia, we found no change in the number of neurons nor the expression of HDC in Orex-HA mice compared to controls. Importantly, no correlation was found in all conditions between HDC and orexin. Our findings indicate that, in mice, the expression of histamine and noradrenalin, two wake-promoting systems, are not modulated by orexin level whether the lack of orexin is constitutive or induced at adult age, showing thus no compensation. They also show no recruitment of histamine by local neuroinflammation. Further studies will be needed to further define the role of histamine in the pathophysiology of NT1.
Published: 2021

10. An augmented food strategy leads to complete energy compensation during a 15‐day military training expedition in the cold

Author: Pauline Oustric, David Thivel, Graham Finlayson, Philippe Colin, Chloé Lavoué, Julien Siracusa, Didier Chapelot, Cyprien Bourrilhon, Keyne Charlot, Thivel, David, Institut de Recherche Biomédicale des Armées (IRBA), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Leeds, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biologie de l'Exercice pour la Performance et la Santé (LBEPS), and Université d'Évry-Val-d'Essonne (UEVE)-Université Paris-Saclay-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)
Subjects: Adult, Male, energy deficiency, Food intake, Physiology, Physical Exertion, Reward value, Energy balance, 030204 cardiovascular system & hematology, Thirst, Fat mass, Eating, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Animal science, rations, Physiology (medical), [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], arctic, energy compensation, QP1-981, Humans, Medicine, military training, ComputingMilieux_MISCELLANEOUS, Carbohydrate intake, Morning, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Original Articles, Cold Temperature, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Military Personnel, Original Article, medicine.symptom, Energy Intake, Energy Metabolism, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery, food preferences, Field conditions
Abstract: Soldiers on military expeditions usually fail to compensate for the increase in energy expenditure, with potential deleterious consequences. We therefore analyzed the characteristics of energy compensation in 12 male soldiers, during a 15‐day expedition in the cold, while alleviating some of the contextual limitations of food intake (~20‐MJ daily bags of easy‐to‐use, highly palatable and familiar foods with multiple and long breaks allowed during the day). Body and fat mass losses were low and moderate, respectively (−1.13 ± 1.42% and −19.5 ± 15.6%, respectively, p, We analyzed the characteristics of energy compensation in 12 male soldiers, during a 15‐day expedition in the cold, while alleviating some of the contextual limitations of food intake (~20‐MJ daily bags of easy‐to‐use, highly palatable and familiar foods with multiple and long breaks allowed during the day). This study indicates that complete energy compensation can be reached in challenging field conditions when food intake is facilitated, offering some guidelines to limit energy deficit during operational missions.
Published: 2021

11. Outcome of patients hospitalized for Covid‐19 and exposure to angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in France: Results of the ACECoV study

Author: Guillaume Moulis, Guillaume Martin-Blondel, Sandrine Charpentier, Agnès Sommet, Pierre Delobel, Margaux Lafaurie, Service de Pharmacologie Médicale et Clinique, CHU Toulouse [Toulouse]-Centre d'Investigation Clinique, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et tropicales [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service des Urgences (TOULOUSE - Urgences), Service de Médecine Interne [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre régional de pharmacovigilance de Grenoble [CHU Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre d'investigation clinique de Toulouse (CIC 1436), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and PINIER, CHRISTINE
Subjects: Male, MESH: Hypertension / complications, pharmacoepidemiology, MESH: COVID-19 / drug therapy, Angiotensin-Converting Enzyme Inhibitors, MESH: Hospitalization, Disease, 030226 pharmacology & pharmacy, SARS‐CoV‐2, law.invention, Cohort Studies, MESH: Aged, 80 and over, 0302 clinical medicine, law, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: COVID-19 / enzymology, Pharmacology (medical), MESH: Respiration, Artificial, MESH: Cohort Studies, MESH: Cardiovascular Diseases / complications, ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, Aged, 80 and over, education.field_of_study, Angiotensin Receptor Antagonists, biology, MESH: Peptidyl-Dipeptidase A / drug effects, Intensive care unit, 3. Good health, Hospitalization, MESH: Peptidyl-Dipeptidase A / metabolism, MESH: Angiotensin Receptor Antagonists / adverse effects, Treatment Outcome, Cardiovascular Diseases, Cohort, Hypertension, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Population study, Female, angiotensin‐receptor blockers, France, medicine.symptom, medicine.medical_specialty, Angiotensins, Critical Care, MESH: COVID-19 / mortality, Population, Subgroup analysis, Inflammation, Peptidyl-Dipeptidase A, MESH: Angiotensin-Converting Enzyme Inhibitors / adverse effects, angiotensin‐converting enzyme inhibitors, 03 medical and health sciences, MESH: Critical Care, COVID‐19, Internal medicine, Renin–angiotensin system, medicine, Humans, cardiovascular diseases, education, Propensity Score, Aged, Pharmacology, MESH: Humans, SARS-CoV-2, business.industry, COVID-19, Angiotensin-converting enzyme, MESH: Propensity Score, medicine.disease, Respiration, Artificial, MESH: Male, Discontinuation, COVID-19 Drug Treatment, MESH: France, Blood pressure, Heart failure, Propensity score matching, biology.protein, business, MESH: Female, 030217 neurology & neurosurgery
Abstract: International audience; Data are lacking on the impact of ACEI/ARB exposure on unfavorable outcome in the population of patients hospitalized for COVID‐19 with hypertension/cardiovascular disease, particularly in Europe. The ACE‐CoV study was designed to assess this question. The study was conducted in the Covid‐Clinic‐Toul cohort, which contains data about all patients hospitalized at Toulouse University hospital, France with a SARS‐CoV‐2 infection since March, 2020. We selected the patients with a history of cardiovascular disease (heart failure or coronary disease) and/or arterial hypertension. We conducted a subgroup analysis in patients with arterial hypertension. ACEI/ARB exposures at admission were assessed. The outcome was composite: admission to intensive care unit, need of mechanical ventilation or death during the 14 days after admission to hospital. We used logistic regression models with propensity scores (PS) weighted by overlap weighting (OW) and inverse probability of treatment weighting (IPTW). Between March 2020 and April 20, 2020, the Covid‐Clinic‐Toul included 263 patients. Among them, 111 were included in the ACE‐CoV study population. In OW‐PS‐adjusted analyses, the association of exposure to ACEIs or ARBs with outcome occurrence was OR: 1.56 (95% CI: 0.73–3.33). It was 0.99 (95% CI: 0.68–1.45) for ACEIs and 1.64 (95% CI: 0.77–3.50) for ARBs. Analyses with weighting by the IPTW‐PS method gave similar results. Results were similar when considering the subgroup of patients with arterial hypertension. The ACE‐CoV study found no association between exposure to ACEIs or ARBs and unfavorable outcome in hospitalized patients for COVID‐19 with a history of cardiovascular disease/arterial hypertension.
Published: 2021
Full Text: View/download PDF

12. Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?

Author: Jérôme Ausseil, Stéphanie Trudel, Fabienne Briand-Mésange, Hugues Chap, Jean-Pierre Salles, Juliette Salles, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and PINIER, CHRISTINE
Subjects: MESH: Coronavirus, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Endocrinology, Diabetes and Metabolism, Adipose tissue, MESH: Endocannabinoids, Medicine (miscellaneous), 030209 endocrinology & metabolism, medicine.disease_cause, Pathogenesis, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Rimonabant, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, MESH: COVID-19, MESH: Obesity, MESH: SARS-CoV-2, MESH: Respiration, Artificial, MESH: Prevalence, 030304 developmental biology, Coronavirus, 0303 health sciences, MESH: Severe Acute Respiratory Syndrome, MESH: Humans, Nutrition and Dietetics, biology, business.industry, MESH: Coronavirus Infections, biology.organism_classification, Endocannabinoid system, Virology, 3. Good health, MESH: Pandemics, MESH: Pneumonia, Viral, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Betacoronavirus, MESH: Rimonabant, business, Betacoronavirus, MESH: Adipose Tissue, medicine.drug
Abstract: International audience; This is the main conclusion of a recent study describing a strong relationship between the degree of obesity and the severity of COVID‐19 infection. Obesity has various negative consequences relative to the course of COVID‐19, including adverse effects on lung physiology, and induces comorbidities such as type II diabetes or hypertension. However, additional mechanisms involving the low‐grade inflammatory state accompanying obesity can also be suggested
Published: 2020
Full Text: View/download PDF

13. Rational Hydrogel Formulation Leads to Reversible and Enhanced Photocontrolled Rigidity

Author: Anne-Françoise Mingotaud, Childérick Séverac, Clément Roux, Florence Benoit-Marquié, Christophe Coudret, Martine Cazales, Corinne Lorenzo, Jorge Royes Mir, Interactions moléculaires et réactivité chimique et photochimique (IMRCP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD), Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Institut des Technologies Avancées en sciences du Vivant (ITAV), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut Ecologie et Environnement (INEE), Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Fédération de Recherche Fluides, Energie, Réacteurs, Matériaux et Transferts (FERMAT), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), IDeAS - Interfaces Dynamiques et Assemblages Stimulables (IDeAS), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Materials science, Polymer science, Organic Chemistry, 02 engineering and technology, 010402 general chemistry, 021001 nanoscience & nanotechnology, 01 natural sciences, 0104 chemical sciences, Analytical Chemistry, [CHIM.POLY]Chemical Sciences/Polymers, Rigidity (electromagnetism), Polymer chemistry, Self-healing hydrogels, Physical and Theoretical Chemistry, [CHIM.OTHE]Chemical Sciences/Other, 0210 nano-technology, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2017

14. The 'Mast Cell and Basophil Club' of the French Society for Immunology

Author: Joana Vitte, S. Georgin-Lavialle, Laurent L. Reber, Ulrich Blank, Michel Arock, Nicolas Gaudenzio, Mei Li, Nicolas Charles, Gaël Ménasché, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Unité différenciation épidermique et auto-immunité rhumatoïde (UDEAR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université - École de médecine (AMU SMPM MED), Aix-Marseille Université - Faculté des sciences médicales et paramédicales (AMU SMPM), Aix Marseille Université (AMU)-Aix Marseille Université (AMU), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Societies, Scientific, MESH: Basophils / immunology, Proteases, Cell Degranulation, International Cooperation, Immunology, Disease, MESH: Allergy and Immunology, Basophil, Immunoglobulin E, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Allergy and Immunology, Hypersensitivity, medicine, Animals, Humans, Immunology and Allergy, MESH: Animals, MESH: Hypersensitivity / immunology, Mast Cells, 030304 developmental biology, 0303 health sciences, MESH: Humans, biology, Cancer, Mast cell, medicine.disease, MESH: Mast Cells / immunology, Basophils, 3. Good health, MESH: France, MESH: Societies, Scientific, MESH: International Cooperation, medicine.anatomical_structure, MESH: Cell Degranulation, biology.protein, France, Homeostasis, 030215 immunology
Abstract: International audience; Mast cells and basophils are best known for their key role during allergic responses [1]. Yet, they also have pivotal functions in innate and acquired (via IgE) defense mechanisms against microbes and parasites as well as in the neutralization of certain toxins such as snake venoms, through the release of proteases and other mediators contained in their cytoplasmic granules [2, 3] (Figure 1, example of a mast cell releasing cytoplasmic granules stained using fluorochrome‐labeled avidin, red). Recent work indicates that these cells have also important functions in a much broader range of inflammatory and pathological conditions including autoimmune diseases, cardiovascular diseases, skin diseases, neuroinflammatory disease and even cancer. However, the mechanisms by which mast cells and basophils mediate their functions in these settings remain largely unknown. Not surprisingly, these new aspects of mast cell and basophil biology have raised interest in the immunology community, with the emergence of new groups focused on studying their involvement in the maintenance of homeostasis and the promotion of disease.
Published: 2020

15. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections

Author: Jacques Izopet, Sébastien Lhomme, Florence Abravanel, Chloé Dimeglio, Pierre Gallian, Azzedine Assal, Pierre Tiberghien, Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang, 20, Avenue du Stade de France, 93218 La Plaine Saint-Denis Cedex, France, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Unité des Virus Emergents (UVE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] (EFS Bordeaux Nouvelle Aquitaine), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), LAB'URBA (LAB'URBA), Université Paris-Est Marne-la-Vallée (UPEM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut de Mathématiques de Toulouse UMR5219 (IMT), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), URA 1164, Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Établissement Français du Sang Alpes-Méditerranée (EFS Alpes-Méditerranée), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), and Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: [SDV]Life Sciences [q-bio], viruses, medicine.disease_cause, Gastroenterology, MESH: Genotype, Hepatitis E virus, Genotype, Blood plasma, MESH: Viral Load / statistics & numerical data, MESH: Hepatitis E / blood, Asymptomatic Infections, ComputingMilieux_MISCELLANEOUS, MESH: France / epidemiology, 0303 health sciences, MESH: Middle Aged, MESH: Hepatitis E virus / genetics, MESH: Asymptomatic Infections / epidemiology, Middle Aged, Viral Load, Hepatitis E, 3. Good health, Infectious Diseases, subgenotype distribution, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, blood donors, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: RNA, Viral / blood, France, MESH: Hepatitis E virus / pathogenicity, medicine.symptom, Viral hepatitis, Viral load, Adult, symptomatic patients, MESH: Humans Immunoglobulin G / blood, medicine.medical_specialty, hepatitis E virus, Asymptomatic, 03 medical and health sciences, Virology, Internal medicine, MESH: Hepatitis E / virology, medicine, Humans, 030304 developmental biology, MESH: Hepatitis E / epidemiology, Hepatitis, Hepatology, 030306 microbiology, business.industry, MESH: Blood Donors, MESH: Adult, medicine.disease, Immunoglobulin G, business
Abstract: International audience; A fraction of plasma donations undergoes hepatitis E virus (HEV) RNA screening since late 2014 in France. The aim of this study was to determine the frequency of HEV RNA as well as the viral load and the evolution of genotype distribution over a 3-year period (2015-2017) in asymptomatic blood donors in comparison with symptomatic patients routinely diagnosed. The overall detection rate of HEV RNA in plasma donations was 0.10% during the 3-year period, with a median viral load of 717 IU/mL (range
Published: 2019

16. No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents

Author: Sébastien Lhomme, Laurent Alric, Laurence Lavayssière, Florence Abravanel, Jacques Izopet, Nassim Kamar, Arnaud Del Bello, Julie Belliere, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Hôpital de Rangueil, CHU Toulouse [Toulouse], Hôpital Purpan [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3)
Subjects: Male, hepatitis C virus, MESH: Antiviral Agents / therapeutic use, Sustained Virologic Response, MESH: Hepatitis C / blood, [SDV]Life Sciences [q-bio], medicine.medical_treatment, MESH: Sustained Virologic Response, 030230 surgery, Liver transplantation, direct acting antiviral agents, medicine.disease_cause, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Hepatitis E virus, MESH: Hepatitis E / blood, MESH: Middle Aged, occult infection, liver transplantation, MESH: Ribavirin / therapeutic use, virus diseases, Hepatitis C, Middle Aged, Hepatitis E, 3. Good health, Infectious Diseases, Liver, MESH: Liver / drug effects, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, Female, MESH: RNA, Viral / blood, 030211 gastroenterology & hepatology, MESH: Hepatitis C / drug therapy, Viral hepatitis, Adult, MESH: Liver Transplantation, medicine.medical_specialty, ribavirin, MESH: Transplant Recipients, Hepatitis C virus, MESH: Hepatitis C / diagnosis, kidney transplantation, hepatitis E virus, Antiviral Agents, MESH: Hepatitis E / diagnosis, MESH: Liver / pathology, MESH: Hepatitis E / drug therapy, 03 medical and health sciences, Internal medicine, medicine, Humans, Hepatitis B virus, Transplantation, MESH: Humans, business.industry, Ribavirin, MESH: Adult, medicine.disease, Transplant Recipients, MESH: Male, digestive system diseases, chemistry, MESH: Liver / virology, business, MESH: Female
Abstract: International audience; Background and aims: It has been recently suggested that occult hepatitis C virus (HCV) infection and hepatitis E virus (HEV) reactivation might occur after direct acting antiviral agent-induced (DAA-induced) sustained virological response (SVR). The aim of our study was to identify occult HCV and HEV infection in a cohort of organ transplant patients who had achieved SVR and had persistent elevation in liver-enzyme levels.Patients and method: Sixty-six liver and/or kidney transplant patients were treated with DAAs. All but one achieved SVR12. Twenty-nine (8-39) months post-SVR12, 8 of the 65 patients (12.3%) who achieved SVR12 had persistently elevated liver enzyme levels. In 1 patient, this was related to hepatitis B virus reactivation. In the 7 remaining patients, blood samples (n = 7), liver biopsies (n = 4), and peripheral blood mononuclear cells (PBMCs) (n = 7) were collected simultaneously in order to identify occult HCV or HEV infection.Results: Hepatitis C virus RNA and HEV RNA were not detected in serum, liver tissues, or PBMCs. No HEV reactivation was observed after HCV clearance in patients who had anti-HEV IgG.Conclusion: Our study suggests that there is no occult HCV or HEV infection in transplant patients after successful treatment of HCV infection with DAAs, even in patients with a persistent elevation of liver enzyme levels. However, due to the small number of patients included in our study, this finding should be confirmed in a larger cohort.
Published: 2019

17. Myelin oligodendrocyte glycoprotein induces incomplete tolerance of CD4 + T cells specific for both a myelin and a neuronal self‐antigen in mice

Author: Liliana E. Lucca, Jens Derbinski, Nicolas Fazilleau, Pierre Rufas, Abdulraouf Ramadan, Roland S. Liblau, Bruno Kyewski, Corine Perals, Lennart T. Mars, Pierre Paul Axisa, Meryem Aloulou, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), XLIM (XLIM), Université de Limoges (UNILIM)-Centre National de la Recherche Scientifique (CNRS), Institut des Sciences du Mouvement Etienne Jules Marey (ISM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Division of Developmental Immunology [Heidelberg, Germany], German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Service de Pneumologie et Réanimation Respiratoire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), and Fazilleau, Nicolas
Subjects: CD4-Positive T-Lymphocytes, 0301 basic medicine, Encephalomyelitis, Autoimmune, Experimental, [SDV.IMM] Life Sciences [q-bio]/Immunology, T cell, Immunology, Population, Gene Expression, T-Cell Antigen Receptor Specificity, Thymus Gland, Biology, Lymphocyte Activation, Autoantigens, Immune tolerance, Myelin oligodendrocyte glycoprotein, Mice, 03 medical and health sciences, Myelin, 0302 clinical medicine, Antigen, Neurofilament Proteins, Immune Tolerance, medicine, Animals, Immunology and Allergy, RNA, Messenger, education, ComputingMilieux_MISCELLANEOUS, Mice, Knockout, Neurons, MHC class II, education.field_of_study, Experimental autoimmune encephalomyelitis, Epithelial Cells, medicine.disease, 030104 developmental biology, medicine.anatomical_structure, biology.protein, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Myelin-Oligodendrocyte Glycoprotein, Myelin Proteins, 030217 neurology & neurosurgery
Abstract: T-cell polyspecificity, predicting that individual T cells recognize a continuum of related ligands, implies that multiple antigens can tolerize T cells specific for a given self-antigen. We previously showed in C57BL/6 mice that part of the CD4(+) T-cell repertoire specific for myelin oligodendrocyte glycoprotein (MOG) 35-55 also recognizes the neuronal antigen neurofilament medium (NF-M) 15-35. Such bi-specific CD4(+) T cells are frequent and produce inflammatory cytokines after stimulation. Since T cells recognizing two self-antigens would be expected to be tolerized more efficiently, this finding prompted us to study how polyspecificity impacts tolerance. We found that similar to MOG, NF-M is expressed in the thymus by medullary thymic epithelial cells, a tolerogenic population. Nevertheless, the frequency, phenotype, and capacity to transfer experimental autoimmune encephalomyelitis (EAE) of MOG35-55 -reactive CD4(+) T cells were increased in MOG-deficient but not in NF-M-deficient mice. We found that presentation of NF-M15-35 by I-A(b) on dendritic cells is of short duration, suggesting unstable MHC class II binding. Consistently, introducing an MHC-anchoring residue into NF-M15-35 (NF-M15-35 T20Y) increased its immunogenicity, activating a repertoire able to induce EAE. Our results show that in C57BL/6 mice bi-specific encephalitogenic T cells manage to escape tolerization due to inefficient exposure to two self-antigens.
Published: 2016

18. The microbiota shifts the iron sensing of intestinal cells

Author: Philippe Langella, Jean-Christophe Deschemin, Gaël Nicolas, Aude Remot, Marie-Louise Noordine, Alexandra Willemetz, Zoubida Karim, Sophie Vaulont, François Canonne-Hergaux, Clément Afif, Muriel Thomas, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (UMR_S567 / UMR 8104), Institut National de la Santé et de la Recherche Médicale (INSERM), European Project: 267196,EC:FP7:PEOPLE,FP7-PEOPLE-2010-COFUND,AGREENSKILLS(2012), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, 0301 basic medicine, Streptococcus thermophilus, Colon, Duodenum, Iron, [SDV]Life Sciences [q-bio], Ferroportin, Faecalibacterium prausnitzii, Biochemistry, Microbiology, law.invention, Mice, 03 medical and health sciences, Probiotic, Intestinal mucosa, law, Genetics, Animals, Intestinal Mucosa, Cation Transport Proteins, Molecular Biology, ferroportin, biology, Microbiota, Cytochromes b, biology.organism_classification, Transport protein, Mice, Inbred C57BL, iron storage, Ferritin, 030104 developmental biology, Liver, Ferritins, iron transporters, biology.protein, Bacteroides, microbes, Biotechnology
Abstract: International audience; The amount of iron in the diet directly influences the composition of the microbiota. Inversely, the effects of the microbiota on iron homeostasis have been little studied. So, we investigate whether the microbiota itself may alter host iron sensing. Duodenal cytochrome b and divalent metal transporter 1, involved in apical iron uptake, are 8- and 10-fold, respectively, more abundant in the duodenum of germ-free (GF) mice than in mice colonized with a microbiota. In contrast, the luminal exporter ferroportin is 2-fold less abundant in GF. The overall signature of microbiota on iron-related proteins is similar in the colon. The colonization does not modify systemic parameters as plasma transferrin saturation (20%), plasma ferritin (150 ng/L), and liver (85 µg/g) iron load. Commensal organisms (Bacteroides thetaiotaomicron VPI-5482 and Faecalibacterium prausnitzii A2-165) and a probiotic strain (Streptococcus thermophilus LMD-9) led to up to 12-fold induction of ferritin in colon. Our data suggest that the intestinal cells of GF mice are depleted of iron and that following colonization, the epithelial cells favor iron storage. This study is the first to demonstrate that gut microbes induce a specific iron-related protein signature, highlighting new aspects of the crosstalk between the microbiota and the intestinal epithelium.
Published: 2015

19. Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation

Author: David Ribes, Joost P. Schanstra, Laurence Lavayssière, Christophe Bureau, Arnaud Del Bello, Laurent Alric, David Milongo, Jean-Loup Bascands, Lionel Rostaing, Adela Ramirez-Torres, Benjamin Breuil, Panagiotis Moulos, Laure Esposito, Fabrice Muscari, Antoine Huart, Nassim Kamar, Justyna Siwy, Hôpital de Rangueil, CHU Toulouse [Toulouse], Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), HybridStat Predictive Analytics [Athens, Greece], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Mosaiques Diagnostics (GmbH), Mosaique Diagnostics, Université Fédérale Toulouse Midi-Pyrénées, Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Hôpital Purpan [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, Proteomics, medicine.medical_specialty, Pathology, Time Factors, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Urinary system, Renal function, Urinalysis, Liver transplantation, Kidney, urologic and male genital diseases, Risk Assessment, Gastroenterology, Liver disease, Predictive Value of Tests, Risk Factors, Internal medicine, medicine, Humans, viral hepatis, Prospective Studies, Renal Insufficiency, Chronic, Aged, liver transplantation, Hepatology, business.industry, Liver Diseases, Middle Aged, medicine.disease, proteome analysis, urine, female genital diseases and pregnancy complications, 3. Good health, Transplantation, Proteinuria, Treatment Outcome, surgical procedures, operative, medicine.anatomical_structure, Female, Viral hepatitis, business, Biomarkers, chronic kidney disease, Glomerular Filtration Rate, Kidney disease
Abstract: Background & Aims Chronic kidney disease (CKD) is a common complication after liver transplantation. Kidney biopsies cannot be easily performed before liver transplantation to predict patients at high risk for CKD. The aim of our study was to determine whether pre-, peri- and post-transplant factors, as well as peptides present in preliver transplant urine samples were associated with loss in kidney function at 6 months post-transplantation using proteome analysis. Methods Eighty patients who underwent a liver transplantation and that had pretransplant glomerular filtration rate (GFR) value of ≥60 mL/min/1.73 m² (MDRD) were included in the study. Results GFR decreased significantly after transplantation. At month 6 post-transplantation, 40 patients displayed a CKD, i.e. eGFR of
Published: 2015

20. Recombinant Ad35 adenoviral proteins as potent modulators of human T-cell activation

Author: Joanne Hay, Darrick Carter, Anne Astier, André Lieber, Health and Safety Executive, Division of Medical Genetics [Seattle], University of Washington [Seattle], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: viruses, T cell, Immunology, T-cell receptor, Original Articles, Biology, Acquired immune system, Molecular biology, female genital diseases and pregnancy complications, 3. Good health, Cell biology, medicine.anatomical_structure, Immune system, T cell differentiation, medicine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Immunology and Allergy, Secretion, IL-2 receptor, Receptor, ComputingMilieux_MISCELLANEOUS
Abstract: The protein CD46 protects cells from complement attack by regulating cleavage of C3b and C3d. CD46 also regulates the adaptive immune response by controlling T cell activation and differentiation. Co-engagement of the T cell receptor and CD46 notably drives T cell differentiation by switching production of IFNγ to secretion of anti-inflammatory IL-10. This regulatory pathway is altered in several chronic inflammatory diseases highlighting its key role for immune homeostasis. The manipulation of the CD46 pathway may therefore provide a powerful means to regulate immune responses. Herein, we investigated the effect of recombinant proteins derived from the fiber knob of the adenovirus serotype 35 (Ad35) that uses CD46 as its entry receptor, on human T cell activation. We compared the effects of Ad35K++, engineered to exhibit enhanced affinity to CD46, and of Ad35K-, mutated in the binding site for CD46. Ad35K++ profoundly affects T cell activation by decreasing the levels of CD46 at the surface of primary T cells, and impairing T cell co-activation, shown by decreased CD25 expression, reduced proliferation and lower secretion of IL-10 and IFNγ. In contrast, Ad35K- acts a potent coactivator of T cells, enhancing T cell proliferation and cytokine production. These data show that recombinant Ad35 proteins are potent modulators of human T cell activation, and support their further development as potential drugs targeting T cell responses. This article is protected by copyright. All rights reserved.
Published: 2014

21. Hepatitis E virus infection as a new probable cause ofde novomembranous nephropathy after kidney transplantation

Author: Karine Moreau, Nassim Kamar, Lionel Couzi, Sébastien Lepreux, B. Taton, Thomas Bachelet, Pascale Trimoulet, Pierre Ronco, A. Pommereau, V. de Ledinghen, Pierre Merville, RONCO, Pierre, CHU Bordeaux [Bordeaux], Centre de traitement des maladies rénales, CTMR Saint-Augustin, Remodelage et Reparation du Tissu Renal, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Université de Toulouse (UT), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, ribavirin, viruses, hepatitis E virus, medicine.disease_cause, Glomerulonephritis, Membranous, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Hepatitis E virus, Membranous nephropathy, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Biopsy, medicine, Humans, Kidney transplantation, 030304 developmental biology, 0303 health sciences, Transplantation, medicine.diagnostic_test, business.industry, Ribavirin, membranous nephropathy, Middle Aged, medicine.disease, Hepatitis E, Kidney Transplantation, 3. Good health, Infectious Diseases, chemistry, Immunology, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], 030211 gastroenterology & hepatology, business, Viral hepatitis, Nephrotic syndrome
Abstract: International audience; Hepatitis E virus (HEV) has been identified as a cause of chronic viral hepatitis in immunocompromised patients. Some glomerular diseases were found to be associated with this infection. We report the first case, to our knowledge, of a kidney transplant recipient who developed an HEV infection and de novo membranous nephropathy (MN) concomitantly. The patient displayed a hepatic cytolysis first and a nephrotic syndrome occurred 3 months later. HEV infection was diagnosed upon positive polymerase chain reaction on plasma and stool samples, and renal allograft biopsy revealed de novo MN. Typical causes of MN were definitively excluded. A 3-month course of ribavirin monotherapy allowed the patient to mount a sustained viral response that was rapidly followed by complete remission of the nephrotic syndrome. The chronology of the onset and remission of both diseases is highly suggestive of a causal relationship between hepatitis E and MN.
Published: 2013

22. DNA polymerase κ-dependent DNA synthesis at stalled replication forks is important for CHK1 activation

Author: Christophe Cazaux, Naoko Niimi, Bénédicte Recolin, Jean Sébastien Hoffmann, Errol C. Friedberg, Petr Grúz, Emma Ohl-Séguy, Takehiko Nohmi, Marie Jeanne Pillaire, Laura Pierini, Caixia Guo, Rémy Betous, Domenico Maiorano, Siem van der Laan, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de génétique humaine (IGH), and Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: DNA Replication, replication stress, DNA polymerase, DNA polymerase II, Chk1, Cell Cycle Proteins, DNA-Directed DNA Polymerase, Xenopus Proteins, Editorials: Cell Cycle Features, DNA polymerase delta, Genomic Instability, General Biochemistry, Genetics and Molecular Biology, Xenopus laevis, 03 medical and health sciences, 0302 clinical medicine, Replication factor C, ssDNA, Animals, Humans, Molecular Biology, ComputingMilieux_MISCELLANEOUS, Cell Proliferation, 030304 developmental biology, [SDV.GEN]Life Sciences [q-bio]/Genetics, 0303 health sciences, General Immunology and Microbiology, biology, General Neuroscience, DNA replication, Processivity, G2-M DNA damage checkpoint, Molecular biology, 3. Good health, ATR, TLS DNA polymerase, 030220 oncology & carcinogenesis, Checkpoint Kinase 1, biology.protein, DNA damage, chromatin, Origin recognition complex, cell cycle, biological phenomena, cell phenomena, and immunity, Protein Kinases, 9-1-1, HeLa Cells
Abstract: Formation of primed single-stranded DNA at stalled replication forks triggers activation of the replication checkpoint signalling cascade resulting in the ATR-mediated phosphorylation of the Chk1 protein kinase, thus preventing genomic instability. By using siRNA-mediated depletion in human cells and immunodepletion and reconstitution experiments in Xenopus egg extracts, we report that the Y-family translesion (TLS) DNA polymerase kappa (Pol κ) contributes to the replication checkpoint response and is required for recovery after replication stress. We found that Pol κ is implicated in the synthesis of short DNA intermediates at stalled forks, facilitating the recruitment of the 9-1-1 checkpoint clamp. Furthermore, we show that Pol κ interacts with the Rad9 subunit of the 9-1-1 complex. Finally, we show that this novel checkpoint function of Pol κ is required for the maintenance of genomic stability and cell proliferation in unstressed human cells.
Published: 2013

23. Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort

Author: Boyer, Jean, Bongard, Vanina, Cantagrel, Alain, Jamard, Bénédicte, Gottenberg, Jacques-Eric, Mariette, Xavier, Davignon, Jean, Ferrières, Jean, Ruidavets, Jean, Dallongeville, Jean, Arveiler, Dominique, Cambon-Thomsen, Anne, Constantin, Arnaud, Saraux, Alain, CHU Toulouse [Toulouse], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Hôpital de Hautepierre [Strasbourg], Hôpital Bicêtre, Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Biomolécules et inflammation pulmonaire, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Progression tumorale et microenvironnement. Approches translationnelles et épidémiologie, Université de Strasbourg (UNISTRA)-CHU Strasbourg-Les Hôpitaux Universitaires de Strasbourg (HUS)-Institut Régional du Cancer-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC), Centre d'Investigation Clinique INSERM 1412 (CIC 1412 - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), An unrestricted grant from Merck Sharp & Dohme (MSD)was allocated for the first 5 years. Two additional grantsfrom INSERM were obtained to support part of the biologicdatabase. The ESPOIR cohort study was also supported bythe French Society of Rheumatology, Abbott, Wyeth-Pfizer,and Roche., We thank Pascale Roux‐Lombard and Jean‐Michel Dayer, Division of Immunology and Allergy, University Hospital of Geneva, Geneva, Switzerland, for quantification of serum IL‐6, and Ms Nathalie Rincheval, Laboratoire Biostatistique et Epidémiologie, Institut Universitaire de Recherche Clinique, Montpellier, France, for data management and technical support. We also wish to thank all of the investigators who recruited and followed the patients (F. Berenbaum, Paris‐Saint Antoine, M.‐C. Boissier, Paris‐Bobigny, B. Combe, Montpellier, M. Dougados, Paris‐Cochin, P. Fardelonne, P. Boumier, Amiens, B. Fautrel, P. Bourgeois, Paris‐La Pitié, R.‐M. Flipo, Lille, Ph. Goupille, Tours, F. Liote, Paris‐Lariboisière, X. Le Loet, O. Vittecoq, Rouen, O. Meyer, Paris‐Bichat, A. Saraux, Brest, Th. Schaeverbeke, Bordeaux, J. Sibilia, Strasbourg, France)., Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Régional du Cancer-Université de Strasbourg (UNISTRA)-CHU Strasbourg-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Blood Glucose, Male, MESH: Inflammation, [SDV]Life Sciences [q-bio], Arthritis, Blood Pressure, 030204 cardiovascular system & hematology, Systemic inflammation, Gastroenterology, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH: Early Diagnosis, MESH: Incidence, MESH: Cohort Studies, MESH: Aged, MESH: Middle Aged, Incidence, MESH: Blood Pressure, Middle Aged, MESH: Case-Control Studies, 3. Good health, Pulse pressure, C-Reactive Protein, Cardiovascular Diseases, Cohort, Female, lipids (amino acids, peptides, and proteins), France, MESH: Cholesterol, HDL, medicine.symptom, MESH: Cholesterol, LDL, Adult, MESH: Triglycerides, medicine.medical_specialty, MESH: Arthritis, 03 medical and health sciences, Rheumatology, Internal medicine, MESH: C-Reactive Protein, medicine, Humans, Risk factor, Triglycerides, Aged, Inflammation, 030203 arthritis & rheumatology, MESH: Humans, Interleukin-6, business.industry, Cholesterol, Cholesterol, HDL, MESH: Cardiovascular Diseases, MESH: Adult, Cholesterol, LDL, medicine.disease, MESH: Interleukin-6, MESH: Male, MESH: France, Early Diagnosis, Blood pressure, Endocrinology, chemistry, Case-Control Studies, MESH: Blood Glucose, business, MESH: Female, Lipoprotein
Abstract: Objective To compare the characteristics of traditional cardiovascular risk factors for untreated patients with early arthritis (EA) and healthy subjects, and to look for a link between cardiovascular risk factors and inflammation in EA patients. Methods This multicenter case–control study enrolled 607 patients with EA (ESPOIR cohort) and 1,821 age- and sex-matched controls (World Health Organization MONICA survey). Lipid levels, blood pressure, glucose levels, and exposure to smoking were characterized in patients and controls. Systemic inflammation was quantified in EA patients. Traditional cardiovascular risk factor characteristics were compared between patients with EA and controls. The link between cardiovascular risk factors and inflammation was assessed in EA patients. Results Mean ± SEM total cholesterol (2.14 ± 0.022 versus 2.34 ± 0.017 gm/liter; P < 0.001), high-density lipoprotein (HDL) cholesterol (0.60 ± 0.011 versus 0.63 ± 0.007 gm/liter; P = 0.020), and low-density lipoprotein (LDL) cholesterol (1.28 ± 0.025 versus 1.51 ± 0.016 gm/liter; P < 0.001) were lower in EA patients than in controls. Triglycerides, triglycerides/HDL ratio, and pulse pressure were higher in patients with EA. Diastolic blood pressure and glucose levels were lower in EA patients. Former or current smokers were more frequent in patients with EA. Total and HDL cholesterol levels were negatively associated with C-reactive protein or serum interleukin-6 levels. Conclusion Total, HDL, and LDL cholesterol, triglycerides, diastolic blood pressure, pulse pressure, glucose, and triglycerides/HDL ratio differ between patients with EA and controls. Some of these risk factors appear to be linked to systemic inflammation. Such initial differences could modulate the risk of cardiovascular events later in the course of arthritis.
Published: 2012

24. High-resolution profiling of γH2AX around DNA double strand breaks in the mammalian genome

Author: Didier Trouche, Jason S. Iacovoni, Imen Lassadi, Estelle Nicolas, Pierre Caron, Gaëlle Legube, Laurent Massip, Institut Fédératif de Recherche Bio-médicale Institution (IFR150), Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de biologie moléculaire eucaryote (LBME), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Caron, Pierre, IFR150, Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)
Subjects: Transcription, Genetic, [SDV]Life Sciences [q-bio], Restriction Mapping, RNA polymerase II, Genome, Article, General Biochemistry, Genetics and Molecular Biology, Cell Line, Histones, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Transcription (biology), Humans, DNA Breaks, Double-Stranded, Phosphorylation, Molecular Biology, Gene, 030304 developmental biology, Transcription bubble, Genetics, 0303 health sciences, General Immunology and Microbiology, biology, General Neuroscience, Chromosome Mapping, Chromatin, Cell biology, [SDV] Life Sciences [q-bio], Histone, chemistry, 030220 oncology & carcinogenesis, biology.protein, DNA
Abstract: International audience; Chromatin acts as a key regulator of DNA-related processes such as DNA damage repair. Although ChIP-chip is a powerful technique to provide high-resolution maps of protein-genome interactions, its use to study DNA double strand break (DSB) repair has been hindered by the limitations of the available damage induction methods. We have developed a human cell line that permits induction of multiple DSBs randomly distributed and unambiguously positioned within the genome. Using this system, we have generated the first genome-wide mapping of gammaH2AX around DSBs. We found that all DSBs trigger large gammaH2AX domains, which spread out from the DSB in a bidirectional, discontinuous and not necessarily symmetrical manner. The distribution of gammaH2AX within domains is influenced by gene transcription, as parallel mappings of RNA Polymerase II and strand-specific expression showed that gammaH2AX does not propagate on active genes. In addition, we showed that transcription is accurately maintained within gammaH2AX domains, indicating that mechanisms may exist to protect gene transcription from gammaH2AX spreading and from the chromatin rearrangements induced by DSBs.
Published: 2010

25. Dynein participates in chromosome segregation in fission yeast

Author: Thibault Courtheoux, Guillaume Gay, Céline Reyes, Sherilyn Goldstone, Yannick Gachet, Sylvie Tournier, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Dynein, MESH: Chromosome Segregation, Mitosis, Cell Cycle Proteins, Spindle Apparatus, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Chromatids, Biology, MESH: Anaphase, Microtubules, Chromosome segregation, 03 medical and health sciences, MESH: Cell Cycle Proteins, Chromosome Segregation, Schizosaccharomyces, Centromere, Sister chromatids, Kinetochores, MESH: Metaphase, Metaphase, 030304 developmental biology, MESH: Mitotic Spindle Apparatus, 0303 health sciences, MESH: Kinetochores, MESH: Microtubules, Kinetochore, 030302 biochemistry & molecular biology, Dyneins, Nuclear Proteins, MESH: Chromatids, MESH: Schizosaccharomyces pombe Proteins, Cell Biology, General Medicine, MESH: Mitosis, MESH: Chromosomes, Fungal, MESH: Dynein ATPase, Spindle apparatus, Cell biology, Spindle checkpoint, MESH: Schizosaccharomyces, MESH: Gene Deletion, Mad2 Proteins, Dynactin, Schizosaccharomyces pombe Proteins, Chromosomes, Fungal, Anaphase, MESH: Nuclear Proteins, Gene Deletion
Abstract: International audience; BACKGROUND INFORMATION: In eukaryotic cells, proper formation of the spindle is necessary for successful cell division. For faithful segregation of sister chromatids, each sister kinetochore must attach to microtubules that extend to opposite poles (chromosome bi-orientation). At the metaphase-anaphase transition, cohesion between sister chromatids is removed, and each sister chromatid is pulled to opposite poles of the cell by microtubule-dependent forces. RESULTS: We have studied the role of the minus-end-directed motor protein dynein by analysing kinetochore dynamics in fission yeast cells deleted for the dynein heavy chain (Dhc1) or the light chain (Dlc1). In these mutants, we found an increased frequency of cells showing defects in chromosome segregation, which leads to the appearance of lagging chromosomes and an increased rate of chromosome loss. By following simultaneously kinetochore dynamics and localization of the checkpoint protein Mad2, we provide evidence that dynein function is not necessary for spindle-assembly checkpoint inactivation. Instead, we have demonstrated that loss of dynein function alters chromosome segregation and activates the Mad2-dependent spindle-assembly checkpoint. CONCLUSIONS: These results show an unexpected role for dynein in the control of chromosome segregation in fission yeast, most probably operating during the process of bi-orientation during early mitosis.
Published: 2007

26. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis

Author: Annie Valette, Philippe Chadebech, Laetitia Brichese, Isabelle Truchet, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), and CHADEBECH, Philippe
Subjects: G2 Phase, Cancer Research, Paclitaxel, Antimetabolites, Cyclin D, Cyclin A, Cyclin B, Apoptosis, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], [SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], [SDV.CAN] Life Sciences [q-bio]/Cancer, Cyclin-dependent kinase, CDC2 Protein Kinase, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], [SDV.BC.BC] Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], Tumor Cells, Cultured, Humans, RNA, Messenger, Cycloheximide, Phosphorylation, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], 2-Aminopurine, [SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Protein Synthesis Inhibitors, Cyclin-dependent kinase 1, biology, urogenital system, Cyclin-dependent kinase 2, DNA, Antineoplastic Agents, Phytogenic, Up-Regulation, 3. Good health, Cell biology, Enzyme Activation, Oncology, Biochemistry, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, embryonic structures, biology.protein, Cyclin-dependent kinase complex, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, biological phenomena, cell phenomena, and immunity, Cyclin A2
Abstract: International audience; Microtubule damages induced by paclitaxel inhibit proteasome-dependent degradation of cyclin B, resulting in a sustained activation of cyclin B/cdc2 kinase and a cell cycle arrest in mitosis. It has been previously shown that this kinase activity is also required for paclitaxel-induced apoptosis. We found here that paclitaxel increased cdc2 mRNA and protein levels and led to an accumulation of cdc2 in the active dephosphorylated form in NIH-OVCAR-3 cells. The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis. This increase in cdc2 synthesis is a consequence of paclitaxel-induced arrest in mitosis. Indeed, dual analysis of DNA and cdc2 protein contents indicated that cdc2 up-regulation occurred in cells arrested with a G2/M DNA content. Furthermore, no up-regulation of cdc2 protein was observed when paclitaxel-treated cells were prevented from entering mitosis by treatment with purvalanol A, a cyclin-dependent kinase (CDK) inhibitor, or stimulated to exit mitosis with 2-AP, a non-specific kinase inhibitor. In addition, when paclitaxel-induced apoptosis was inhibited by Bcl-2 over-expression, cdc2 up-regulation did not occur, leading to a lower level of activation of the cyclin B/cdc2 complex. Taken together, these results indicated that paclitaxel-induced cdc2 protein synthesis participates in a positive feedback loop designed to increase the activity of cyclin B/cdc2 kinase and thus may play a role in paclitaxel-induced apoptosis.
Published: 2000

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

26 results on '"Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )"'

1. Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome‐enriched vesicles

2. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer

3. No survival improvement in patients with high‐risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades

4. Understanding human γδ T cell biology toward a better management of cytomegalovirus infection

5. Deciphering human γδ T cell response in cancer: Lessons from tumor‐infiltrating γδ T cells

6. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort

7. Curing inflammatory diseases using phosphorous dendrimers

8. Does HEV‐3 subtype play a role in the severity of acute hepatitis E?

9. Histamine in murine narcolepsy: What do genetic and immune models tell us?

10. An augmented food strategy leads to complete energy compensation during a 15‐day military training expedition in the cold

11. Outcome of patients hospitalized for Covid‐19 and exposure to angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in France: Results of the ACECoV study

12. Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?

13. Rational Hydrogel Formulation Leads to Reversible and Enhanced Photocontrolled Rigidity

14. The 'Mast Cell and Basophil Club' of the French Society for Immunology

15. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections

16. No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents

17. Myelin oligodendrocyte glycoprotein induces incomplete tolerance of CD4 + T cells specific for both a myelin and a neuronal self‐antigen in mice

18. The microbiota shifts the iron sensing of intestinal cells

19. Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation

20. Recombinant Ad35 adenoviral proteins as potent modulators of human T-cell activation

21. Hepatitis E virus infection as a new probable cause ofde novomembranous nephropathy after kidney transplantation

22. DNA polymerase κ-dependent DNA synthesis at stalled replication forks is important for CHK1 activation

23. Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort

24. High-resolution profiling of γH2AX around DNA double strand breaks in the mammalian genome

25. Dynein participates in chromosome segregation in fission yeast

26. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

26 results on '"Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources